# Table of Contents

## SECTION I: Fundamentals of US Pharmaceutical and Biologics Regulations

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Updated by</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>History of Food, Drug and Cosmetic Laws</td>
<td>Meredith Brown-Tuttle, RAC, FRAPS</td>
</tr>
<tr>
<td>2</td>
<td>Overview of Drug, Biologic, Device, Combination Product or Food Regulatory Pathways</td>
<td>Michael R. Hamrell, PhD, RQAP-GCP, CCRA, FACRP, RAC, FRAPS</td>
</tr>
<tr>
<td>3</td>
<td>Clinical Trials: GCPs, Regulations and Compliance for Drugs, Biologics and Medical Devices</td>
<td>Monique Carter, MS, RAC and Samantha Zappia, MS, RAC</td>
</tr>
<tr>
<td>4</td>
<td>Current Good Manufacturing Practices and Quality System Design</td>
<td>Joscelyn Bowersock, MS-RA, and Richard Vincins, CQP, MCQL, CBA, CQA, RAC</td>
</tr>
<tr>
<td>5</td>
<td>Prescription Product Drug Submissions</td>
<td>Shyamala Jayaraman, PhD, Lean Six Sigma Black Belt and Glen D. Park, PharmD, MSJ</td>
</tr>
<tr>
<td>6</td>
<td>Postapproval Submissions and Compliance: Prescription Drugs and Biologics</td>
<td>Emily Rapp, RAC and Dar Rosario, MBA, RAC</td>
</tr>
<tr>
<td>7</td>
<td>Generic Drug Submissions</td>
<td>Amrita Ghosh, RAC and Sharry Arora, MPharm</td>
</tr>
<tr>
<td>8</td>
<td>Patents and Exclusivity</td>
<td>Kurt R. Karst, JD</td>
</tr>
<tr>
<td>9</td>
<td>Over-the-Counter (Nonprescription) Drug Products</td>
<td>Valerie Ramsey, DRSc, MS, RAC</td>
</tr>
<tr>
<td>10</td>
<td>Prescription Drug Labeling, Advertising and Promotion</td>
<td>Anu Gaur, PhD, MBA, MSRA, RAC</td>
</tr>
<tr>
<td>11</td>
<td>Pharmacovigilance and Risk Management</td>
<td>Stacy Woeppel, MBA and Robert Falcone, PhD</td>
</tr>
<tr>
<td>12</td>
<td>Biologics Submissions</td>
<td>Jocelyn Jennings, MS, RAC</td>
</tr>
</tbody>
</table>
Chapter 7  Health Product Vigilance and Risk Management .......................................................... 69
  Updated by Christopher Antonio, Roshni Celeste, Jenna Griffiths, Carole Légaré, Marc Poitras,
  Tanya Ramsamy, Thanh Vu, Bruce Wozny and Raymond Yang

Chapter 8  An Overview of Pharmaceutical Intellectual Property Protection in Canada.................. 79
  By Junyi Chen, JD, PhD, Danny Germain, RAC, Gordon Jepson, MA, LLB, and Bhavesh Patel, CChem

Chapter 9  Abbreviated New Drug Submissions ........................................................................ 95
  Updated by Bhavesh Patel, CChem, Bocar Guisse, Msc and Fraidianie Sevigne

Chapter 10 Nonprescription Drugs .......................................................................................... 105
  Updated by Kristin Willemsen

Chapter 11 Biologics Submission, Approval and Postmarketing .................................................. 115
  Updated by Marcia Sam and Mabdis Dorkalam, MSc, RHN

Chapter 12 Labelling, Advertising and Promotion: Prescription Pharmaceutical Drugs, Biologics
  and Radiopharmaceuticals ......................................................................................................... 127
  Updated by Marcia Sam, Veronica Yip and Sandra Alderdice

Chapter 13 electronic Common Technical Document (eCTD) ..................................................... 133
  By Khaled Yahiaoui, MSc, RAC

Chapter 14 Product Lifecycle Management Guidance .................................................................. 143
  By Ajay Babu Pazhayattil, Nabeed Sayeed-Desta and Queenia Lee

Index ............................................................................................................................................. 149

Figures
Figure 1-1. Health Canada ............................................................................................................. 2
Figure 1-2. Branches with Responsibility for the Regulation of Healthcare Products ......................... 3
Figure 5-1. Diagram of the NDS Submission and Approval Procedure ............................................ 51
Figure 5-2. Example Boxed Text for Product Approved Under the NOC/c Policy .............................. 52
Figure 6-1. Form IV Patent List ..................................................................................................... 64
Figure 13-1. Structure of a Regulatory Transaction in eCTD Format ................................................. 135
Figure 13-2. End-to-End Process for Preparing and Filing Regulatory Transactions in eCTD Format .... 141

Tables
Table 1-1. Timeline—Regulating Health Products in Canada ......................................................... 6
Table 2-1. Examples of Studies and the Requirement for GLP Compliance ....................................... 14
Table 3-1. Contents of a CTA Submission Package ......................................................................... 22
Table 3-2. Quality Changes—Biologics and Radiopharmaceuticals .................................................... 24
Table 3-3. Quality Changes—Pharmaceuticals ................................................................................. 25
Table 3-4. Postapproval Requirements ............................................................................................ 27
Table 4-1. Definitions for Terms in This Chapter .......................................................................... 30
Table 4-2. GMP Regulations Applicable to Licensable Activities ..................................................... 33
Table 5-1. Presentation of Information in the Common Technical Document (CTD) Format ............... 49
Table 5-2. Target Review Times ....................................................................................................... 53
Table 7-1. Clinical Trial Definitions ................................................................................................ 71
Table 7-2. Postapproval Stage Definitions ....................................................................................... 74
Table 9-1. Target Review Times .................................................................................................................. 102
Table 10-1. NAPRA Scheduling Factors........................................................................................................ 110
Table 11-1. Drug Substance (Biologics and Radiopharmaceuticals)............................................................. 118
Table 11-2. Drug Product (Biologics and Radiopharmaceuticals)................................................................. 119
Table 11-3. Sample Table of Contents for a Schedule D (Biological) Product Monograph (PM) ............... 120
Table 11-4. Summary of Requirements for Evaluation Groups ................................................................... 123
Table 13-1. Localization of Main XML Files Within an eCTD Sequence ..................................................... 136
Table 13-2. Canadian eCTD Envelope Elements ......................................................................................... 136
Table 13-3. m2-m5 eCTD Attributes ........................................................................................................... 137
Table 13-4. Validation Rule Samples and Their Descriptions and Severities .......................................... 137
Table 13-5. Document Formats Health Canada Expects for Specific Documents .................................... 138
Table 13-6. Lifecycle Management Table Template .................................................................................. 138
Table 13-7. Lifecycle Management Table Example with Three Regulatory Activities and Related Regulatory Transactions ......................................................................................................................... 139
Table 13-8. Lifecycle Management of Specific Documents ....................................................................... 140

- **SECTION III: Fundamentals of EU Pharmaceutical and Biologics Regulations**
  See Volume 2 of *Fundamentals of Pharmaceutical and Biologics Regulations*

- **SECTION IV: Fundamentals of International Pharmaceutical and Biologics Regulations**
  See Volume 2 of *Fundamentals of Pharmaceutical and Biologics Regulations*
Table of Contents

SECTION I: Fundamentals of US Pharmaceutical and Biologics Regulations
See Volume 1 of Fundamentals of Pharmaceutical and Biologics Regulations

SECTION II: Fundamentals of Canadian Pharmaceutical and Biologics Regulations
See Volume 1 of Fundamentals of Pharmaceutical and Biologics Regulations

SECTION III: Fundamentals of EU Pharmaceutical and Biologics Regulations

Chapter 1 EMA and Other Regulatory Bodies ................................................................. 1
   Updated by Ratinder Dhami, MSRA, RAC

Chapter 2 History of EU Regulations .............................................................................. 13
   Updated by Sabina Hoekstra-van den Bosch, PharmD, FRAPS

Chapter 3 Overview of Drug and Biologic Regulatory Pathways ................................... 31
   Updated by Kathrin Schalper, PhD, RAC

Chapter 4 Preparing for EMA Meetings Prior to Submission of a Marketing Authorisation Application ............. 41
   Updated by Kell Cannon, Kate Dion and Cindy DiBiasi

Chapter 5 Preparing for EMA Meetings During Review of a Marketing Authorisation Application ............... 53
   By Kell Cannon, Kate Dion and Cindy DiBiasi

Chapter 6 EU Pricing and Reimbursement ..................................................................... 61
   Updated by Anu Gaur, PhD, MBA, MSRA, RAC

Chapter 7 Health Technology Assessment (HTA) ................................................................ 77
   Updated by Azzurra Ravizza, MSc and Monique Carter, MS, RAC

Chapter 8 The Paediatric Regulation .............................................................................. 93
   Updated by Karl-Heinz Huemer, PhD, MD
Chapter 9  Advertising and Promotion................................................................................................................103
Updated by Karen Zhou, JD, MS, RAC

Chapter 10  Enforcement and Competent Authorities ........................................................................................115
Updated by Sabina Hoekstra-van den Bosch, PharmD, FRAPS

Chapter 11  European Union Falsified Medicines Directive: Requirements and Implications for Multi-Stakeholder Healthcare Delivery...........................................................................................................................121
Updated by Yolanda García Barruso

Chapter 12  Regulatory Strategy ...........................................................................................................................135
Updated by Karen Fan, MSc, PEng, RAC

Chapter 13  Overview of Authorisation Procedures for Medicinal Products ........................................................141
Updated by Sharry Arora, MPharm

Chapter 14  Adaptive and Alternative Pathways ...................................................................................................159
Updated by Kathrin Schalper, PhD, RAC

Chapter 15  Preclinical Testing and Good Laboratory Practice Regulations........................................................165
Updated by Anu Gaur, PhD, MBA, MSRA, RAC

Chapter 16  Medicinal Product Clinical Trials ......................................................................................................173
Updated by Ashley Clark, MSc, RAC

Chapter 17  Registration Procedures for Medicinal Products................................................................................205
Updated by Jocelyn Jennings, MS, RAC

Chapter 18  Quality Systems and Inspectorate Process—Pharmaceuticals ..........................................................227
Updated by Treena Jackson, MS, MA, CQA, CSSGB, RAC and Siegfried Schmitt, PhD

Chapter 19  Generic Medicinal Products ..............................................................................................................241
Updated by Nicole Beard MSc, PhD

Chapter 20  Biosimilar Medicinal Products...........................................................................................................257
Updated by Jocelyn Jennings, MS, RAC

Chapter 21  Nonprescription Medicinal Products ................................................................................................267
Updated by Nicole Beard MS, PhD

Chapter 22  Marketing Authorisations for Products Derived From Biotechnology ..............................................277
Updated by Jocelyn Jennings, MS, RAC

Chapter 23  Pharmaceutical Postauthorisation Requirements and Compliance With the Marketing Authorisation...........................................................................................................................287
Updated by Sharry Arora, MPharm

Chapter 24  Pharmacovigilance ............................................................................................................................301
Updated by Jocelyn Jennings, MS, RAC

Chapter 25  Regulatory Framework for Advanced Therapy Medicinal Products ..................................................315
By Daniela Drago, PhD, RAC, Florence Houn, MD, MPH and James McBlane, PhD
Chapter 26  Human Tissue Regulation .................................................................................................................335
Updated by Nicole Beard, MSc, PhD

Chapter 27  Vaccines .............................................................................................................................................353
Updated by Frédéric Béard

Chapter 28  Products Manufactured From Human Blood or Plasma ...................................................................365
Updated by Nicole Beard, MSc, PhD

Chapter 29  Orphan Medicinal Products ..............................................................................................................375
Updated by Jocelyn Jennings, MS, RAC

Chapter 30  Combination Products .......................................................................................................................389
Updated by Claudia Ising, FRAPS, RAC

Glossary ....................................................................................................................................................................399

Index.........................................................................................................................................................................419

Figures
Figure 1-1.  EMA Mission........................................................................................................................................3
Figure 1-2.  EMA Organisational Structure .............................................................................................................9
Figure 5-1.  Approximate Representation of Key CHMP, CAT and PRAC Feedback and Meetings Based on
Standard Assessment Review Timeline ...............................................................................................55
Figure 5-2.  Example Timeline for CHMP Meeting Preparation ........................................................................57
Figure 6-1.  Factors Influencing Medicinal Product Pricing ......................................................................................62
Figure 6-2.  Overview of ERP across Europe (2013) .............................................................................................64
Figure 6-3.  Summary of Economic Evaluation Methods........................................................................................66
Figure 6-4.  Types of Cost Containment Policies Adopted by Member States ..........................................................67
Figure 6-5.  German Pricing for Medicinal Products Under AMNOG .................................................................70
Figure 7-1.  Process Map for France .......................................................................................................................85
Figure 7-2.  Process Map for Germany ....................................................................................................................86
Figure 7-3.  Mean Length of Time From EMA Authorisation to HTA Decision for Oncology Products ..........88
Figure 8-1.  PIP Procedure.......................................................................................................................................98
Figure 11-1. Comparison of EU FMD and Other Countries’ Falsified Medicines Legislation .............................123
Figure 11-2. Routes in the Medicinal Product Supply Chain by Which Falsified Active Substances may
Reach Patients ...................................................................................................................................125
Figure 11-3. An Example of the Common Logo Online Retailers of Medicines Must Display...........................128
Figure 11-4. Flowchart Representing Product and Information Flow With Unique Product Identifiers and
Accompanying Verification and Repository Systems .....................................................................................131
Figure 14-1. Product Eligibility for Adaptive Pathways Approach (Source: EMA, 2016) .....................................161
Figure 16-1 Clinical Trial Legislative Improvements ..............................................................................................176
Figure 16-2 Regulation (EU) 536/2014 ...................................................................................................................177
Figure 16-3 Clinical Trial Authorization Procedure ..................................................................................................190
Figure 16-4 Clinical Trial Application Scientific Assessment ................................................................................191
Figure 16-5 Clinical Trial Application: Part II Assessment .....................................................................................192
Figure 16-6. Serious Adverse Event Reporting .......................................................................................................196
Figure 17-1. Initial Marketing Authorisation Application Through the Centralised Procedure ............................219
Figure 17-2. Initial Marketing Authorisation Application Through the Decentralised Procedure ........................220
Chapter 8: Regulatory Reliance

By Daniela Drago, PhD, RAC and Murray M. Lumpkin, MD, MSc

Chapter 9: Pricing and Reimbursement

Updated by Anu Gaur, PhD, MBA, MSRA, RAC

Chapter 10: Health Technology Assessment (HTA)

Updated by Azzurra Ravizza, MSc and Monique Carter, MS, RAC

Chapter 11: Premarket Requirements/Dossier Requirements

Updated by Monique Carter, MS, RAC and Jesshanie Tabaniag

Chapter 12: Authorization Procedures for Pharmaceutical Products

Updated by Orin Chisholm, GCULT, PhD, MTOPRA, SFHEA and Monique Carter, MS, RAC, MTOPRA

Chapter 13: Stability Test Requirements

Updated by Sharry Arora, MPharm and Rosie Dawes

Chapter 14: Quality Systems and Inspectorate Process for Pharmaceuticals

Updated by Siegfried Schmitt, PhD

Chapter 15: Generic Drug Products

Updated by Pallavi Trivedi, MPH, RAC and Anu Gaur, PhD, MBA, MSRA, RAC

Chapter 16: Over-the-Counter (OTC) Products

Updated by Robert Falcone, PhD

Chapter 17: Pharmaceutical Postmarketing and Compliance

Updated by Kathrin Schalper, PhD, RAC

Chapter 18: High-Risk Products: Products Derived from Biotechnology

Updated by Jocelyn Jennings, MS, RAC and Angela L. Nelson, MBA, RAC

Chapter 19: Biosimilars: Basics and Recent Developments

Updated by Pallavi Trivedi, MPH, RAC

Chapter 20: Vaccines

Updated by Nicole Beard, MSc, PhD

Chapter 21: Products Manufactured from Human Blood and Plasma

Updated by Indraneel Dasari, RAC

Chapter 22: Principles of Rare Diseases and Orphan Products Development

Updated by Todd J. Banks, PharmD, RPh, Ken Bonnell, MS, MBA, and Phu Bo Chung, JD, MS, RAC

Chapter 23: Combination Products

Updated by Deanna Hughes, MS, RAC and Beat U. Steffen, MSc, MBA

Chapter 24: Regulatory Considerations for Cell-Based Medicinal Products

By Indraneel Dasari, RAC
Table 23-3. Applicable Articles When the Medicinal Product is Ancillary .......................................................... 432
Table 23-4. Applicable Articles for Devices to Administer Medicinal Products ................................................ 434
Table 24-1. Approved ATMPs in the US, EU, and Japan .................................................................................... 443
Table 24-2. Doses of Medical Products Comprising Human Cells, Genes, and Tissues ...................................... 444
Table 24-3. Summary of Risk Factors Associated with Transmission of COVID-19 During Manufacturing of ATMPs ................................................................................................................................ 446
Table 24-4. Proposed Risk Classification for ATMPs with Respect to COVID-19 ............................................ 446
Table 24-5. Overview of Applicable Regulatory Guidelines in the US, EU, and Japan ........................................ 447
Table 24-6. EU Regulatory Scenarios ................................................................................................................. 449
Table 24-7. US Regulatory Scenarios .................................................................................................................. 451
Table 24-8. Overview of Applicable US Regulatory Guidelines ......................................................................... 452
Table 24-9. Overview of Applicable EU Regulatory Guidelines ......................................................................... 453
Table 24-10. Overview of Applicable Regulatory Guidelines in Japan .............................................................. 455
Table 25-1. Traditional Herbal or Botanical Product Regulations in Selected Countries ...................................... 463
Table 25-2. Direct-to-OTC Criteria for BDPs With Only Non-US Experience ................................................... 469
Table 25-3. Strategic Considerations for Developing a BDP for US Approval .................................................. 472
Table 25-4. Comparison of BDPs and Conventional Drugs .............................................................................. 473
Table 26-1. FDA Pediatric Age Categories for Labeling of Drugs and Biologics ................................................ 486
Table 26-2. Timeline of Key Pediatric Drug Development Initiatives, Guidances, and Legislative Actions Undertaken in the US ................................................................................................................................ 487
Table 26-3. Overview of BPCA and PREA ......................................................................................................... 489
Table 26-4. Outline of the initial Pediatric Study Plan (iPSP) ............................................................................. 492
Table 26-5. Timeline of Key Pediatric Initiatives Undertaken in the EU ............................................................. 493
Table 26-6. Pediatric Regulation–Key Requirements and Incentives ................................................................... 494
Table 26-7. Overview of Information Required in a PIP ..................................................................................... 498